Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
5Annual filing director officer or owner of more than ten percent.Feb 12, 2016View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 12, 2016View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 12, 2016View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 12, 2016View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 12, 2016View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 10, 2016View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 10, 2016View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventJan 7, 2016View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventJan 7, 2016View HTMLDownload DOCDownload PDFDownload XLS
3Initial filing by director officer or owner of more than ten percent.Jan 6, 2016View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJan 6, 2016View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-100      101-125      126-136

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information